Add to ORKG•44 year old woman treated with bevacizumab for metastatic epithelial ovarian cancer•The patient experienced vaginal cuff dehiscence and evisceration at 8 months post-operatively.•Metastasis at the surgical site and chronic inflammation implicated
Purpose: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improv...
Robin A Laskey,1 Scott D Richard,2 Ashlee L Smith,1 Jeff F Lin,1 Tiffany L Beck,3 Jamie L Lesnock,1 ...
Most ovarian cancer cases are diagnosed at an advanced stage (III or IV), in which a primary debulki...
•44 year old woman treated with bevacizumab for metastatic epithelial ovarian cancer•The patient exp...
Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic trea...
In this retrospective study, we investigated adverse events and outcomes in patients treated with be...
Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian can...
The Gynecologic Oncology Group conducted this phase II trial to estimate the anti-tumor activity of ...
Background: Initial experiences reported increased surgical morbidities in patients receiving cytore...
Background: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of b...
The aim of this study was to assess the safety and efficacy of extending bevacizumab therapy beyond ...
Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical ...
AbstractBackgroundThe main objective of this study was to determine the incidence of severe toxicity...
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and...
ABSTRACT Background Chemotherapy with carboplatin, paclitaxel, and bevacizumab is the standard the...
Purpose: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improv...
Robin A Laskey,1 Scott D Richard,2 Ashlee L Smith,1 Jeff F Lin,1 Tiffany L Beck,3 Jamie L Lesnock,1 ...
Most ovarian cancer cases are diagnosed at an advanced stage (III or IV), in which a primary debulki...
•44 year old woman treated with bevacizumab for metastatic epithelial ovarian cancer•The patient exp...
Treatment of multiresistant ovarian cancer is palliative and patients have needs for less toxic trea...
In this retrospective study, we investigated adverse events and outcomes in patients treated with be...
Bevacizumab (Bev) is an antiangiogenic drug used to treat various malignances, including ovarian can...
The Gynecologic Oncology Group conducted this phase II trial to estimate the anti-tumor activity of ...
Background: Initial experiences reported increased surgical morbidities in patients receiving cytore...
Background: Angiogenesis plays a role in the biology of ovarian cancer. We examined the effect of b...
The aim of this study was to assess the safety and efficacy of extending bevacizumab therapy beyond ...
Hiroyuki Yoshida, Akira Yabuno, Keiichi FujiwaraDepartment of Gynecologic Oncology, Saitama Medical ...
AbstractBackgroundThe main objective of this study was to determine the incidence of severe toxicity...
Bevacizumab (BV) is a humanized monoclonal antibody targeting vascular endothelial growth factor and...
ABSTRACT Background Chemotherapy with carboplatin, paclitaxel, and bevacizumab is the standard the...
Purpose: We evaluated whether adding bevacizumab to current platinum-based chemotherapy could improv...
Robin A Laskey,1 Scott D Richard,2 Ashlee L Smith,1 Jeff F Lin,1 Tiffany L Beck,3 Jamie L Lesnock,1 ...
Most ovarian cancer cases are diagnosed at an advanced stage (III or IV), in which a primary debulki...